Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of inhibitor of mir-497-5p and its application in the preparation of medicine for treating liver fibrosis

A technology of mir-497 and liver fibrosis, which is applied in the field of preparation of liver fibrosis drugs, can solve the problems of different functions and the difficulty of miRNA

Active Publication Date: 2021-04-06
XUZHOU MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Although it is known in the art that some microRNAs have a certain correlation with liver fibrosis, there are many kinds of miRNAs known in the art with different functions, and it is necessary to screen out miRNAs that are related to fibrosis and can be used as pathogenesis and treatment options. It is difficult to select and predict miRNA
At present, there is no report in the field on the treatment and prognosis of liver fibrosis based on the inhibition of miR-497 function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of inhibitor of mir-497-5p and its application in the preparation of medicine for treating liver fibrosis
  • A kind of inhibitor of mir-497-5p and its application in the preparation of medicine for treating liver fibrosis
  • A kind of inhibitor of mir-497-5p and its application in the preparation of medicine for treating liver fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] 1. Reagents and materials

[0040] Reagent

[0041] Fetal bovine serum (Hyclone, USA); complete medium: add 100ml of fetal bovine serum, 0.15g of L-glutamine, 10.0ml of 2-mercaptoethanol (5×10 -3 mol / L); Liposome 2000 (Invitrogen, USA); Penicillin, Streptomycin (Shanghai Sangon Biotechnology Co., Ltd); TRIzol (Invitrogen, USA); Agarose (Spain); Sucrose, Triton-100, Triton (Hydroxymethyl)aminomethane (Tris), hydrochloric acid, EDTA, NaCl, phenol, chloroform, isoamyl alcohol, sodium dodecylsulfonate (SDS) and absolute ethanol are all analytically pure or superior Pure; SYBR GreenⅠ fluorescence quantification kit (Roche, USA), miRNA reverse transcription kit (Beijing Tiangen Biochemical Technology Company); dual luciferase reporter gene detection kit (Promega, USA); pmiRGLO Smad7wt, mut plasmid ( Shanghai Jierui Bioengineering Co., Ltd.); miRNA-497 miminc and miRNA-497 inhibitor (miRNA-497 inhibitor) were synthesized by Gemma Gene. PCR primers were synthesized by Shang...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biotechnology, and in particular relates to an inhibitor of miR-497-5p and its use in the preparation of drugs for treating liver fibrosis. After extensive and in-depth research, the present invention finds for the first time that the inhibitor can complement the miR-497-5p sequence, inhibit the function of miR-497-5p and promote the expression of Smad7, and the inhibitor can significantly inhibit hepatic stellate cells ( The main cells that produce extracellular matrix such as type I and type III collagen fibrils) activate and secrete type I collagen fibers, thereby improving liver fibrosis. That is to say, the present invention discovers for the first time the new application of miR-497-5p inhibitor in the preparation of drugs for treating liver fibrosis.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to the use of miR-497-5p inhibitors in the preparation of liver fibrosis medicines. Background technique [0002] MicroRNA (microRNA, miRNA) is a kind of small non-coding RNA with a length of about 22 nt, which exists in most eukaryotic cells and can regulate gene expression at the post-transcriptional level. In the nucleus, RNA polymerase II first transcribes the DNA fragment encoding miRNA into an initial transcription product pri-miRNA with a length of about 300-1000 bp, and the pri-miRNA is processed by nuclease Drosha to form a miRNA of about 70-90 bp After the pre-miRNA is transported out of the nucleus by the nuclear transport protein exportin 5, it is processed into a 20-25 bp double-stranded miRNA by the nuclease Dicer, and one of the double strands is combined with the RNA silencing complex (RNA- The induced silencing complex (RISC) forms a RISC-miRNA complex and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/7088A61P1/16
CPCA61K31/7088A61K45/00A61P1/16
Inventor 郑葵阳颜超汤仁仙沈莉萍于倩李向阳华慧张波
Owner XUZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com